Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of…
MIAMI, July 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and…